After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results

412
146
Favorite

After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results

StreetInsider2022-05-24

After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

412

Report

Comment（146）

VivianChua
·2022-05-24
Soon will be improving 💚💚💚
Reply
Like
Report
YueShan
·2022-05-24
Hope can recover
Reply
Like
Report
Simonnov
·2022-05-24
Ok
Reply
Like
Report
N00b
·2022-05-24
Ok
Reply
1
Report
Gerinit
·2022-05-24
Pls like. Thanks
Reply
2
Report
Jess261
·2022-05-24
Okay
Reply
1
Report
Siak
·2022-05-24
K
Reply
2
Report
SSVC
·2022-05-24
K
Reply
2
Report
KingJo
·2022-05-24
Ohh
Reply
3
Report
Newnew
·2022-05-24
Hi
Reply
2
Report
Aloynty
·2022-05-24
As quickly as it recovered, tech is back in the reds; can't afford to lose the support else it's bear territory for a while
Reply
3
Report
RW5
·2022-05-24
O
Reply
1
Report
Harry S
·2022-05-24
Okay
Reply
1
Report
WannaBluffy
·2022-05-24
👍
Reply
1
Report
Shindokai
·2022-05-24
Like
Reply
2
Report
Alex1225
·2022-05-24
Like pls
Reply
5
Report
Joney时不利兮骓不逝
·2022-05-24
ok
Reply
5
Report
Zeruel
·2022-05-24
Like pls
Reply
6
Report
YLim
·2022-05-24
K
Reply
7
Report
Nagoken
·2022-05-24
Hhello
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2237369545?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-24 07:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2237369545","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNAP","symbol_name":"Snap Inc","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","article_id":"2237369545","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","pubTimestamp":1653347322,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNAP":"Snap Inc","GOOGL":"谷歌A","ZM":"Zoom","TWTR":"Twitter"},"translate_title":"下班后的股票搬运工：SNAP的警告让整个科技界不寒而栗；缩放结果增益","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZM":1,"FB":0.9,"GOOGL":0.9,"SNAP":0.9,"TWTR":0.9},"content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9026656537,"gmtCreate":1653370507929,"gmtModify":1676535270006,"author":{"id":"3580011914778910","authorId":"3580011914778910","name":"VivianChua","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3580011914778910","authorIdStr":"3580011914778910"},"htmlText":"Soon will be improving 💚💚💚","listText":"Soon will be improving 💚💚💚","text":"Soon will be improving 💚💚💚","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026656537","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026629504,"gmtCreate":1653368123508,"gmtModify":1676535269560,"author":{"id":"3583033297199166","authorId":"3583033297199166","name":"YueShan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3583033297199166","authorIdStr":"3583033297199166"},"htmlText":"Hope can recover&nbsp;","listText":"Hope can recover&nbsp;","text":"Hope can recover","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026629504","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026690611,"gmtCreate":1653360631633,"gmtModify":1676535268258,"author":{"id":"4097750438225520","authorId":"4097750438225520","name":"Simonnov","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097750438225520","authorIdStr":"4097750438225520"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026690611","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026843400,"gmtCreate":1653357658400,"gmtModify":1676535267465,"author":{"id":"4102702385674620","authorId":"4102702385674620","name":"N00b","avatar":"https://community-static.tradeup.com/news/2fff337dda34fd1714aa113e5b234fc9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4102702385674620","authorIdStr":"4102702385674620"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026843400","repostId":2237369545,"repostType":2,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026829049,"gmtCreate":1653355888881,"gmtModify":1676535266901,"author":{"id":"4102323649583470","authorId":"4102323649583470","name":"Gerinit","avatar":"https://static.tigerbbs.com/32f151d5c2b15c07d43c4d7f9f49fbab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4102323649583470","authorIdStr":"4102323649583470"},"htmlText":"Pls like. Thanks","listText":"Pls like. Thanks","text":"Pls like. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026829049","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026866181,"gmtCreate":1653355459643,"gmtModify":1676535266786,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026866181","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026869557,"gmtCreate":1653355093779,"gmtModify":1676535266545,"author":{"id":"3586817050833129","authorId":"3586817050833129","name":"Siak","avatar":"https://static.tigerbbs.com/ed2639a3eeb56c6706ffb23a3d0059fd","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3586817050833129","authorIdStr":"3586817050833129"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026869557","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026815266,"gmtCreate":1653354073355,"gmtModify":1676535266210,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026815266","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026819250,"gmtCreate":1653353420970,"gmtModify":1676535266061,"author":{"id":"3559556416091691","authorId":"3559556416091691","name":"KingJo","avatar":"https://static.tigerbbs.com/b0c610addd66a5842a11cbf8ce38b5f0","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":1,"idStr":"3559556416091691","authorIdStr":"3559556416091691"},"htmlText":"Ohh","listText":"Ohh","text":"Ohh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026819250","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026895314,"gmtCreate":1653352481538,"gmtModify":1676535265595,"author":{"id":"3583016139705080","authorId":"3583016139705080","name":"Newnew","avatar":"https://static.tigerbbs.com/c1f72fa81dd8aa4df22904e9ff7b7c9b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583016139705080","authorIdStr":"3583016139705080"},"htmlText":"Hi&nbsp;","listText":"Hi&nbsp;","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026895314","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026802160,"gmtCreate":1653351818150,"gmtModify":1676535265387,"author":{"id":"3575873871496945","authorId":"3575873871496945","name":"Aloynty","avatar":"https://community-static.tradeup.com/news/8bc156c78f1b8fc5d20a5b2da3a5b6aa","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3575873871496945","authorIdStr":"3575873871496945"},"htmlText":"As quickly as it recovered, tech is back in the reds; can't afford to lose the support&nbsp;else it's bear&nbsp;territory for a while","listText":"As quickly as it recovered, tech is back in the reds; can't afford to lose the support&nbsp;else it's bear&nbsp;territory for a while","text":"As quickly as it recovered, tech is back in the reds; can't afford to lose the support else it's bear territory for a while","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026802160","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026801251,"gmtCreate":1653351664573,"gmtModify":1676535265289,"author":{"id":"3582440300426753","authorId":"3582440300426753","name":"RW5","avatar":"https://static.tigerbbs.com/1892f1a4f1e18bdabb9f243266c5c6b3","vip":1,"hat":"https://static.tigerbbs.com/1c1eed764d9c7ff83dc093fbb9a96bc2","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582440300426753","authorIdStr":"3582440300426753"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026801251","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026146333,"gmtCreate":1653350616622,"gmtModify":1676535264758,"author":{"id":"4101691105425760","authorId":"4101691105425760","name":"Harry S","avatar":"https://static.tigerbbs.com/30f2206e539f2175ef68264baf0a18f7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4101691105425760","authorIdStr":"4101691105425760"},"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026146333","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026141480,"gmtCreate":1653350508040,"gmtModify":1676535264727,"author":{"id":"3586986998667843","authorId":"3586986998667843","name":"WannaBluffy","avatar":"https://static.tigerbbs.com/1dd14463a45a95644b65d2bd68777ecd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586986998667843","authorIdStr":"3586986998667843"},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026141480","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026143273,"gmtCreate":1653350435892,"gmtModify":1676535264711,"author":{"id":"3576820982022251","authorId":"3576820982022251","name":"Shindokai","avatar":"https://static.tigerbbs.com/548d3e56658ca7df99ec4ad0e0b65d4d","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3576820982022251","authorIdStr":"3576820982022251"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026143273","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026149467,"gmtCreate":1653350377160,"gmtModify":1676535264695,"author":{"id":"3581747766858829","authorId":"3581747766858829","name":"Alex1225","avatar":"https://static.tigerbbs.com/4a6d122a9e87329fc98cd47b2cd58d8f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581747766858829","authorIdStr":"3581747766858829"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026149467","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026140426,"gmtCreate":1653350306565,"gmtModify":1676535264680,"author":{"id":"3583126720118354","authorId":"3583126720118354","name":"Joney时不利兮骓不逝","avatar":"https://community-static.tradeup.com/news/141712a74548a707a89b626125595a51","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583126720118354","authorIdStr":"3583126720118354"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026140426","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026140189,"gmtCreate":1653350260841,"gmtModify":1676535264672,"author":{"id":"3581585697986903","authorId":"3581585697986903","name":"Zeruel","avatar":"https://static.tigerbbs.com/eecf09841f50906eaebded07a6c16ff0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581585697986903","authorIdStr":"3581585697986903"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026140189","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026140092,"gmtCreate":1653350251916,"gmtModify":1676535264656,"author":{"id":"3576017864370659","authorId":"3576017864370659","name":"YLim","avatar":"https://static.tigerbbs.com/e6b6104d6aeb4bffcce051d8b3b7fbdd","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3576017864370659","authorIdStr":"3576017864370659"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026140092","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9026154982,"gmtCreate":1653350135346,"gmtModify":1676535264605,"author":{"id":"3576560237263785","authorId":"3576560237263785","name":"Nagoken","avatar":"https://static.tigerbbs.com/caac3ac5db4b0d37985b9f55a62d569f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576560237263785","authorIdStr":"3576560237263785"},"htmlText":"Hhello","listText":"Hhello","text":"Hhello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9026154982","repostId":2237369545,"repostType":4,"repost":{"id":"2237369545","kind":"highlight","pubTimestamp":1653347322,"share":"https://ttm.financial/m/news/2237369545?lang=&edition=fundamental","pubTime":"2022-05-24 07:08","market":"us","language":"en","title":"After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2237369545","media":"StreetInsider","summary":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance o","content":"<html><head></head><body><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/SNAP\">Snap</a> 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.</p><p><a href=\"https://laohu8.com/S/INMB\">INmune Bio, Inc.</a> 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.</p><p><a href=\"https://laohu8.com/S/NLS\">Nautilus</a> 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.</p><p><a href=\"https://laohu8.com/S/PINS\">Pinterest, Inc.</a> 12% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> 7% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ZM\">Zoom</a> 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. <a href=\"https://laohu8.com/S/ZM\">Zoom</a> sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.</p><p><a href=\"https://laohu8.com/S/GOOGL\">Google</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/TWTR\">Twitter</a> 4% LOWER; falls on Snap&#39;s Q2 warning.</p><p><a href=\"https://laohu8.com/S/ALB\">Albemarle</a> Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-24 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20118094><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20118094\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNAP":"Snap Inc","ZM":"Zoom","TWTR":"Twitter","GOOGL":"谷歌A"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20118094","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2237369545","content_text":"After-Hours Stock Movers:Snap 30% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated. As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range.INmune Bio, Inc. 22% LOWER; announced that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company’s Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer’s Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro™ remains open in Australia and continues to enroll patients.Nautilus 20% LOWER; reported Q4 EPS of ($0.58), in-line with the analyst estimate of ($0.58). Revenue for the quarter came in at $119.7 million versus the consensus estimate of $120.85 million.Pinterest, Inc. 12% LOWER; falls on Snap's Q2 warning.Meta Platforms 7% LOWER; falls on Snap's Q2 warning.Zoom 5% HIGHER; reported Q1 EPS of $1.03, $0.16 better than the analyst estimate of $0.87. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Zoom sees Q2 2023 EPS of $0.90-$0.92, versus the consensus of $0.88. Zoom sees Q2 2023 revenue of $1.115-1.12 billion, versus the consensus of $1.11 billion. Zoom sees FY2023 EPS of $3.70-$3.77, versus the consensus of $3.53. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.55 billion.Google 4% LOWER; falls on Snap's Q2 warning.Twitter 4% LOWER; falls on Snap's Q2 warning.Albemarle Corporation 3% HIGHER; further revised its full-year 2022 guidance today, reflecting mainly the completion of additional lithium contract renegotiations with its lithium customers following its Q1/22 earnings release on May 4, 2022. Net sales are now expected to be in the range of $5.8 - $6.2 billion versus the prior outlook of $5.2 - $5.6 billion and the consensus of $5.44 billion. Adjusted EBITDA is now seen in the range of $2.2 - $2.5 billion versus the prior guidance of $1.7 - $2.0 billion. Adjusted diluted EPS in the range of $12.30 - $15.00 versus the consensus of $10.88 and prior guidance of $9.25 - $12.25.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":412,"commentSize":146,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}